Despite this, since the NR2B subunit of the NMDA receptor is crucial in the progression of AD through calcium influx, antagonists of NR2B are being considered for therapeutic applications in this disease (3, 51, 52). This evidence concerns the gene GRIN2B and Alzheimer disease.